Antitumor Necrosis Factor Monoclonal Antibody Therapy in a Woman with Severe Adamantiades-Behçet’s Disease

Author(s):  
F. Behrens ◽  
T. Zollner ◽  
B. Moeller ◽  
J. P. Kaltwasser ◽  
R. Kaufmann ◽  
...  
2017 ◽  
Vol 263 ◽  
pp. e140-e141
Author(s):  
Fulya Balaban Yucesan ◽  
Asim Orem ◽  
Deniz Aksu Arica ◽  
Buket Altinkaynak ◽  
Burak Aksan ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Olfat G. Shaker ◽  
Shereen O. Tawfic ◽  
Amira M. El-Tawdy ◽  
Mohamed H. M. El-Komy ◽  
Manal El Menyawi ◽  
...  

Background. Tumor necrosis factor-alpha (TNF-α) is an important proinflammatory cytokine which plays an important role in the immunopathogenesis of Behcet’s disease (BD). B cell activating factor (BAFF) and its homolog A proliferation inducing ligand (APRIL) are members of the tumor necrosis factor family. BAFF binds to 3 receptors, B cell activating factor receptor (BAFF-R), transmembrane activator and calcium modulator ligand interactor (TACI), and B cell maturation antigen (BCMA) that are expressed by B cells.Objective. Estimation of the serum levels of TNF-α, APRIL, BAFF, and BCMA in patients with BD in an effort to evaluate their degree of involvement in the pathogenesis and development of BD.Patients and Methods. This study included 30 male patients fulfilling the international study group criteria for the diagnosis of BD. Twenty age-matched healthy male volunteers served as control. Serum samples were used for quantification of TNF-α, APRIL, BCMA, BAFF, and hsCRP using ELISA techniques.Results. The mean serum levels of TNF-α, APRIL, BCMA, and BAFF were more elevated in cases than in controls in a statistically significant manner(P<0.001). Positive correlation was observed between hs-CRP and BDCAF (Behcet’s disease current activity forum) index (r0.68,P<0.001). None of the TNF family members tested was affected by a positive pathergy test.Conclusions. Patients have significantly higher levels of TNF family members’ (TNF-α, BAFF, APRIL, and BCMA) compared to controls which might contribute to the pathogenesis of BD.


2017 ◽  
Vol 69 (12) ◽  
pp. 2380-2385 ◽  
Author(s):  
Petros P. Sfikakis ◽  
Aikaterini Arida ◽  
Stylianos Panopoulos ◽  
Kalliopi Fragiadaki ◽  
George Pentazos ◽  
...  

2009 ◽  
Vol 58 (3) ◽  
pp. 371-373 ◽  
Author(s):  
Joanne Malkin ◽  
Anna Shrimpton ◽  
Martin Wiselka ◽  
Michael R. Barer ◽  
Michael Duddridge ◽  
...  

We present a case of Mycobacterium kansasii olecranon bursitis in a woman with known immunosuppression secondary to the treatment received for her Behçet's disease. We found only one other case report of olecranon bursitis caused by M. kansasii in the literature, which, unlike our case, presented in an immunocompetent adult following trauma. This case extends the range of opportunistic mycobacterial infections that are associated with anti-tumour necrosis factor therapy.


2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Daniel Sánchez-Cano ◽  
José Luis Callejas-Rubio ◽  
Ricardo Ruiz-Villaverde ◽  
Raquel Ríos-Fernández ◽  
Norberto Ortego-Centeno

Tumoral necrosis factorαplays a central role in both the inflammatory response and that of the immune system. Thus, its blockade with the so-called anti-TNF agents (infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab) has turned into the most important tool in the management of a variety of disorders, such as rheumatoid arthritis, spondyloarthropatties, inflammatory bowel disease, and psoriasis. Nonetheless, theoretically, some other autoimmune disorders may benefit from these agents. Our aim is to review these off-label uses of anti-TNF blockers in three common conditions: Behçet’s disease, sarcoidosis, and noninfectious uveitis. Due to the insufficient number of adequate clinical trials and consequently to their lower prevalence compared to other immune disorders, this review is mainly based on case reports and case series.


1999 ◽  
Vol 54 (3) ◽  
pp. 264-272 ◽  
Author(s):  
D.H. Verity ◽  
G.R. Wallace ◽  
R.W. Vaughan ◽  
E. Kondeatis ◽  
W. Madanat ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document